Recent share performance and business scale Taiwan Semiconductor Manufacturing (TSM) has recently faced a 6.2% one day share decline, adding to a month drop of about 15%, even as the stock remains higher over the past 3 months. Over the past year, the company reports a total return of about 96%, with multi year total returns that are several times the starting value. Recent moves come against a ba...
Recent share performance and business scale Taiwan Semiconductor Manufacturing (TSM) has recently faced a 6.2% one day share decline, adding to a month drop of about 15%, even as the stock remains higher over the past 3 months. Over the past year, the company reports a total return of about 96%, with multi year total returns that are several times the starting value. Recent moves come against a backdrop of sizeable operations across global semiconductor markets. See our latest analysis for...
Cathie Wood just dialed back one of Big Tech’s biggest names again. The ARK Invest boss shed 3,578 shares of Meta Platforms (META) on March 25, a move worth nearly $2.1 million. The sale was spread across three of ARK’s major actively managed ETFs, with Meta coming off a lean patch, having ...
Cathie Wood just dialed back one of Big Tech’s biggest names again. The ARK Invest boss shed 3,578 shares of Meta Platforms (META) on March 25, a move worth nearly $2.1 million. The sale was spread across three of ARK’s major actively managed ETFs, with Meta coming off a lean patch, having ...
According to the current regulations, Sword Group announces that its 2025 Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the website of the company: 2025 FINANCIAL REPORT
According to the current regulations, Sword Group announces that its 2025 Financial Report has been made available to the public. It was sent to the Commission de Surveillance du Secteur Financier (CSSF) and was also filed with the Luxembourg Stock Exchange. It can be viewed and downloaded on the website of the company: 2025 FINANCIAL REPORT
The S&P 500 Index ($SPX ) (SPY ) today is down -0.79%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.12%. June E-mini S&P futures (ESM26 ) are down -0.74%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.79%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.12%. June E-mini S&P futures (ESM26 ) are down -0.74%, and June E-mini Nasdaq futures...
Steam rises from a stack outside the POET LLC ethanol biorefinery in Gowrie, Iowa, U.S., on Friday, May 17, 2019. Stockpiles of U.S. corn ethanol sank to the smallest since July even as production of the biofuel climbed, Department of Energy data showed on Wednesday.
Steam rises from a stack outside the POET LLC ethanol biorefinery in Gowrie, Iowa, U.S., on Friday, May 17, 2019. Stockpiles of U.S. corn ethanol sank to the smallest since July even as production of the biofuel climbed, Department of Energy data showed on Wednesday.
RHJ/iStock via Getty Images Wheaton Precious Metals ( WPM ) up 4.6% in Friday's trading as UBS upgraded shares to Buy from Neutral with a $160 price target, saying it expects the company to enter a volume growth phase targeting ~70% growth in gold equivalent oz by 2030 compared to FY 2025, which should drive superior earnings vs. peers without further upside in gold or silver prices. Gold equivale...
RHJ/iStock via Getty Images Wheaton Precious Metals ( WPM ) up 4.6% in Friday's trading as UBS upgraded shares to Buy from Neutral with a $160 price target, saying it expects the company to enter a volume growth phase targeting ~70% growth in gold equivalent oz by 2030 compared to FY 2025, which should drive superior earnings vs. peers without further upside in gold or silver prices. Gold equivalent production has remained rangebound at 600K-700K oz over the past five years, while Wheaton ( WPM ) has traded at 22x 12-month forward consensus enterprise value to EBITDA, with earnings growth driven by higher precious metal prices; the stock currently trades at ~15x 2027 enterprise value to EBITDA, representing a 30% discount to its five-year average, and UBS analyst Daniel Major said the market is not pricing in the company's diversified and low-risk organic growth. Wheaton ( WPM ) is differentiated from large-cap gold miners and streamers by the magnitude and diversification of its growth, which Major said reduces execution risk as no single project dominates the company's growth profile; the analyst expects the company to acquire more streams and royalties to supplement growth, reducing single-asset exposure and earnings volatility. More on Wheaton Precious Metals Wheaton Precious Metals: Gift Of The Cartel Wheaton Precious Metals: Wait For Risk Claification Wheaton Precious Metals Q4 2025 Earnings Call Presentation
simpson33/iStock via Getty Images This is my eighth Organogenesis ( ORGO ) article, following most recently 12/2025's "Organogenesis: High-Tech Skin Substitute Company On Sale ." I have been emboldened rather than discouraged by its ~50% drop since On Sale was published. The big question is whether it's a bargain or a falling knife. After smashing Q4 2025 revenue expectations, guidance coldcocked ...
simpson33/iStock via Getty Images This is my eighth Organogenesis ( ORGO ) article, following most recently 12/2025's "Organogenesis: High-Tech Skin Substitute Company On Sale ." I have been emboldened rather than discouraged by its ~50% drop since On Sale was published. The big question is whether it's a bargain or a falling knife. After smashing Q4 2025 revenue expectations, guidance coldcocked Organogenesis shares Organogenesis reported a superlative Q4 2025 with revenues that handily surpassed analysts's expectations; the release reported: Revenue of $225.1 million (+77.7% Y/Y), a beat of $52.42 million, and Q4 GAAP EPS of $0.24, a beat of $0.03. Its release reported this great news and then added a spoiler in terms of the very important outlook for the upcoming year 2026. In this regard, the release turned downbeat when it guided expectations for 2026, as stated below: Fiscal Year 2026 Outlook: For the year ending December 31, 2026, the Company expects: Total net revenue between $350.0 million and $420.0 million, representing a decline in the range of 25% to 38%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025 . (emphasis added) The 2026 total net revenue guidance range assumes a significant year-over-year decline in revenue for the three months ending March 31, 2026, and strong quarter-over-quarter growth in the second, third and fourth quarters of fiscal year 2026. A revenue drop of up to 38% is a huge deal, particularly in today's economic climate garbled by the war in the Middle East. Insofar as the release was issued nearly 2/3rds of the way through Q1 2026 on 2/26/2026, its Q1 2026 was mostly already in the bag at the time it published this outlook. In other words, its outlook for the quarter was likely based on more than dour speculation. It's no easy task to wrap one's mind around this report's significance for Organogenesis' expected subsequent quarterly revenues. Its annual revenues for 2026 were estimated at $3...
Forty-two years ago, right about now, I was a third-year law student trading options between classes as if they were cold Cokes on a sweltering day. I loved the semiconductors back then — National Semi, Texas Instruments, and Motorola. I also worshipped IBM, always long those calls, and Monolithic Memories was my favorite spec. It's good to have one spec. I was crushing it, able to pay off my Banc...
Forty-two years ago, right about now, I was a third-year law student trading options between classes as if they were cold Cokes on a sweltering day. I loved the semiconductors back then — National Semi, Texas Instruments, and Motorola. I also worshipped IBM, always long those calls, and Monolithic Memories was my favorite spec. It's good to have one spec. I was crushing it, able to pay off my Banco Popular, Chase, Chemical, and Harvard Trust credit cards, only three left, and crunched a chunk of student debt, too. But then I had the misfortune to have a toothache, and a classmate of mine said, "Go see Dr. Traurig in Back Bay, he's the best." It was one of the worst financial decisions I have ever made, not because Traurig cost a fortune, he really did, but because he had a financial magazine in the waiting room, and the cover story told you that it was time to cash in on tech. It was too dangerous. People were making so much money, being greedy, but a squall was coming, one that could morph into a Cat 5 hurricane any minute. I remember cursing myself for getting drilled right into the close of trading and having to wait until the next day to extricate myself from all the tech call options. That magazine, that skeptical journalist, the one who pronounced it a watershed moment for technology, kept me from paying off the rest of my credit card debt before I got to New York to start working full-time at Goldman Sachs . Sure enough, he was right. Tech was dead, at least for the next three weeks. Then it rose, like Lazarus, and went on for another 42 years, meaning, until now. The question for me is: How many people have been blown out like me in that dentist's chair? Scared and frightened, the only way to relieve the pain is to sell. That's the real reason why so few people make money in the stock market. I now stick with the best of tech. You know why? Not because tech is something special. But because there is a group of amazing companies at any given time with tremend...